Sunesis Pharmaceuticals market cap is $96.3 m, and annual revenue was $120 k in FY 2020

Sunesis Pharmaceuticals Net income (FY, 2020)-21.6 M

Sunesis Pharmaceuticals EBIT (FY, 2020)-22.3 M

Sunesis Pharmaceuticals Cash, 31-Dec-202020.4 M

Sunesis Pharmaceuticals EV76.5 M

USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|---|---|---|---|---|---|---|

## Revenue | 5.0m | 3.8m | 8.0m | 5.7m | 3.1m | 2.5m | 669.0k | 237.0k | 2.1m | 120.0k |

## R&D expense | 22.6m | 29.2m | 28.9m | 27.7m | 23.7m | 22.9m | 21.5m | 14.6m | 15.4m | 12.3m |

## General and administrative expense | 8.3m | 9.2m | 10.8m | 23.1m | 18.7m | 16.1m | 13.5m | 11.3m | 9.9m | 10.2m |

## Operating expense total | 30.9m | 38.4m | 39.7m | 50.8m | 42.4m | 39.0m | 35.1m | 25.9m | 25.4m | 22.4m |

## EBIT | (25.9m) | (34.6m) | (31.8m) | (45.0m) | (39.3m) | (36.5m) | (34.4m) | (25.7m) | (23.3m) | (22.3m) |

| (517%) | (922%) | (399%) | (786%) | (1284%) | (1438%) | (5145%) | (10848%) | (1123%) | (18586%) |

## Interest expense | 109.0k | 1.9m | ||||||||

## Pre tax profit | (34.6m) | (43.0m) | (36.7m) | (38.0m) | (35.5m) | (26.6m) | (23.3m) | (21.6m) | ||

## Income tax expense | ||||||||||

## Net Income | (20.1m) | (44.0m) | (34.6m) | (43.0m) | (36.7m) | (38.0m) | (35.5m) | (26.6m) | (23.3m) | (21.6m) |

USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|---|---|---|---|---|---|---|

## Net Income | (20.1m) | (44.0m) | (34.6m) | (43.0m) | (36.7m) | (38.0m) | (35.5m) | (26.6m) | (23.3m) | (21.6m) |

## Depreciation and Amortization | 56.0k | 31.0k | 20.0k | 29.0k | 27.0k | 11.0k | 9.0k | 9.0k | (70.0k) | (41.0k) |

## Accounts Payable | 242.0k | (580.0k) | 875.0k | 2.2m | (724.0k) | (582.0k) | (174.0k) | (304.0k) | (602.0k) | (312.0k) |

## Cash From Operating Activities | (22.8m) | (10.6m) | (37.4m) | (43.2m) | (38.7m) | (37.0m) | (36.1m) | (24.4m) | (22.2m) | (21.4m) |

## Purchases of PP&E | (15.0k) | (48.0k) | (26.0k) | |||||||

## Cash From Investing Activities | 4.2m | (21.4m) | 32.2m | 3.3m | 1.2m | (15.0m) | 29.7m | 4.8m | (16.3m) | 16.4m |

## Short-term Borrowings | (7.2m) | (9.4m) | (1.6m) | (8.0m) | (7.6m) | (7.5m) | (5.5m) | |||

## Cash From Financing Activities | 13.7m | 37.6m | 5.4m | 46.9m | 42.2m | 33.1m | 25.3m | 6.3m | 43.0m | 7.2m |

## Net Change in Cash | (4.9m) | 5.6m | 181.0k | 7.1m | 4.7m | (18.8m) | 18.9m | (13.3m) | 4.6m | 2.1m |

## Interest Paid | 109.0k | 1.2m | 2.0m | 1.2m | 631.0k | 1.2m | 1.1m | 790.0k | 695.0k | 339.0k |

USD | Q2, 2011 |
---|---|

## Financial Leverage | 1.3 x |